American Society of Tropical Medicine and Hygiene, 2018.
سنة النشر:
2018
الوصف:
It remains a global health priority to develop a durable and highly efficacious malaria vaccine. The most advanced malaria vaccine candidate, RTS,S/AS01 has completed Phase III testing in a multicentre study across several African sites and demonstrates low-level (~30%) efficacy against clinical malaria in children aged 5-17 months after a three dose schedule. Efficacy wanes rapidly over time and there remain some safety concerns that require further assessment in the planned pilot deployment trials due to commence in Africa in 2018.